The objectives of this study were to 1) determine if hypertensive patients with comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) receiving a pharmacist intervention had a greater reduction in mean blood pressure (BP) and improved BP control at 9 months compared to those receiving usual care and 2) compare Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) guideline and 2014 guideline (JNC-8) BP control rates in patients with DM and/or CKD.
This cluster, randomized trial included 32 medical offices in 15 states. Clinical pharmacists made treatment recommendations to physicians at intervention sites. This post-hoc analysis evaluated mean BP and BP control rates in the intervention and control groups.
The study included 335 patients (227 intervention, 108 control) when mean BP and control rates were evaluated by JNC-7 inclusion and control criteria. When JNC-8 inclusion and control criteria were applied, 241 patients (165 intervention, 76 control) remained and were included in the analysis. The pharmacist-intervention group had significantly greater mean SBP reduction compared to usual care at 9 months (8.64 mm Hg [95% Confidence interval (CI)= -12.8, -4.49, p<0.001]). The pharmacist-intervention group had significantly higher BP control at 9 months than usual care by either the JNC-7 or JNC-8 inclusion and control groups (adjusted odds ratio (OR) 1.97 [95% CI= 1.01, 3.86]; p=0.0470 and 2.16 [95%CI= 1.21, 3.85]; p=0.0102, respectively).
This study demonstrated that a physician-pharmacist collaborative intervention was effective in reducing mean systolic BP and improving BP control in patients with uncontrolled hypertension with DM and/or CKD, regardless of which BP guidelines were used. This article is protected by copyright. All rights reserved.
Pharmacology, Toxicology and Pharmaceutical Science
31
18%
Medicine and Dentistry
25
15%
Nursing and Health Professions
12
7%
Biochemistry, Genetics and Molecular Biology
3
2%
Chemistry
3
2%
Other
14
8%
Unknown
81
48%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2023.
All research outputs
#2,904,292
of 34,376,207 outputs
Outputs from Pharmacotherapy
#379
of 3,217 outputs
Outputs of similar age
#46,134
of 372,325 outputs
Outputs of similar age from Pharmacotherapy
#8
of 37 outputs
Altmetric has tracked 34,376,207 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,217 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 372,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
